psilocybin


Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle

August 8th, 2022 - Ryan Allway

VANCOUVER, British Columbia, Aug. 08, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experiences, is pleased to announce that it has entered […]

Item 9 Labs Corp. Nears Completion of Cannabis Cultivation and Lab Facility in Pahrump, Nevada

July 13th, 2022 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – July 13, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFD) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, is pleased to announce that the Silo Wellness team coordinated the presentations of eight speakers in support of psilocybin use under Ballot Measure 109 in Lane County, Oregon, […]

Silo Wellness Organizes Jamaican Psilocybin Retreat Team and Advocates to Speak to Lane County (Eugene, Oregon) Commissioners Regarding BM109 Optout Vote; Lane County Declines to Refer a Psilocybin Ban to Voters

July 13th, 2022 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – July 13, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFD) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, is pleased to announce that the Silo Wellness team coordinated the presentations of eight speakers in support of psilocybin use under Ballot Measure 109 in Lane County, Oregon, […]

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre

July 13th, 2022 - Ryan Allway

  Partnership a unique opportunity to showcase Canada as a clinical and cultivation mecca   July 13, 2022 VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company cultivating and synthesizing high quality psychedelics and natural functional and psilocybin mushroom strains for transformational human experiences, […]

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder

June 27th, 2022 - Ryan Allway

— Marks the first novel psilocybin analog to enter clinical development — — Patient recruitment to commence immediately — — Pharmacokinetic and safety data readout expected in Q4 2022 —     TORONTO, June 27, 2022–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that it […]

Nirvana Life Sciences announces filing of Patent for novel isolation of 4-PO-Psilocin Prodrug Compound

June 23rd, 2022 - Ryan Allway

VANCOUVER, BC, June 23, 2022 /CNW/ – Nirvana Life Sciences Inc. (Nirvana or the “Company”) (CSE: NIRV) a western Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to report that it has filed a provisional patent application for a novel process for the isolation of a psychedelic 4-PO-Psilocin […]

Tryp Therapeutics Appoints New Chief Operating Officer

June 23rd, 2022 - Ryan Allway

Sid Taubenfeld with Extensive Experience in the Financial Markets and as a Biotech Executive Joins Tryp as Company Prepares to Expand Patient Access to Psilocybin-Based Treatments San Diego, California — (June 23, 2022) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases […]

Silo Wellness Requests Oregon Property Owner Expressions of Interest for Collaborating on Psilocybin Licensing; Other Corporate Updates

June 14th, 2022 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – June 14, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, announces a request for expressions of interests from Oregon property owners who may be considering participation in the regulatory regime under Oregon Ballot Measure 109. “With Silo Wellness […]

TRYP Therapeutics Announces results of First Patient Dosed in its Phase II Clinical Trial for the Treatment of Binge Eating Disorder

June 9th, 2022 - Ryan Allway

  Initial data readout supports the potential effectiveness of psilocybin and psilocybin-related compounds for the treatment of Binge Eating Disorder San Diego, California — (June 9, 2022) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the […]

Nirvana Life Sciences Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study

June 2nd, 2022 - Ryan Allway

Psilocybin reduced reinstatement of Heroin seeking behavior when administered immediately after a memory retrieval task in rats.   VANCOUVER, BC, June 2, 2022 /CNW/ – Nirvana Life Sciences Inc. (Nirvana or the “Company”) (CSE: NIRV),  a Canadian based life sciences company focused on developing novel therapeutic products derived from psychedelics to produce non-addictive solutions for opioid addiction […]

Irwin Naturals Files Q1 2022 Financials

May 30th, 2022 - Ryan Allway

Cannabis Licensing and Ketamine Clinic Rollup Strategy Accelerating Growth Company to host conference call Tuesday, May 31, 2022 at 2:00 pm EST LOS ANGELES, May 30, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced the Company filed results for its first quarter of fiscal 2022, the period ended […]

Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.

May 27th, 2022 - Ryan Allway

Halucenex to receive recently harvested first batch of psilocybe cubensis May 27, 2022 VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with Halucenex […]

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

May 12th, 2022 - Ryan Allway

— Review of Phase I ready BMB-101 and upcoming milestones — — Webcast to be held on May 19, 2022, 4:00pm ET —     VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs […]

Optimi Health Granted Amendment To Controlled Substances Dealer’s Licence

May 4th, 2022 - Ryan Allway

Request to modify quantities of psilocybin and psilocin receives approval from Health Canada.   VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that a requested Amendment to its Controlled Substances Dealer’s Licence has been granted by Health Canada, enabling it to further expand the capacity to […]

Irwin Naturals to File Q4 and Full Year Results for Fiscal 2021

May 3rd, 2022 - Ryan Allway

Conference Call on Tuesday, May 3, 2022 at 2:00pm EST LOS ANGELES, May 03, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) today announced the Company will file its results for the fiscal fourth quarter and full year 2021, the period ended December 31, 2021, on Tuesday May […]

Adastra Announces Completed Submission of Controlled Substances Dealer’s License Application

March 25th, 2022 - Ryan Allway

LANGLEY, BC, March 25, 2022 /CNW/ – Adastra Holdings Ltd. (CSE: XTRX) (FRA: D2EP) (“Adastra” or the “Company”) a Health Canada Licensed cannabis company focused on processing, sales, organoleptic testing and analytical testing, is pleased to announce it completed the submission of its application for a Controlled Drugs and Substances Dealer’s License (“Dealer’s License”) on March 23, 2022. […]

PsyBio Therapeutics Reports Annual 2021 Financial Results

March 2nd, 2022 - Ryan Allway

OXFORD, Ohio and COCONUT CREEK, Fla., March 2, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announces that it […]

Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program

February 16th, 2022 - Ryan Allway

  VANCOUVER, BC (GLOBE NEWSWIRE – February 16, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report that Health Canada has added the Company’s wholly-owned subsidiary Optimi Labs […]

Filament Health Announces Health Canada Approval For Phase II Trial Administering New Psilocybin Microdose Formulation

January 4th, 2022 - Ryan Allway

  The clinical trial at the University of Toronto will study low doses of psilocybin in healthy subjects with persistent depressive disorder   VANCOUVER, BC, Jan. 4, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that Health Canada has approved a phase 2 clinical […]

Silo Wellness Announces Latest Psychedelic Retreat Offerings

December 16th, 2021 - Ryan Allway

Montego Bay, Jamaica–(Newsfile Corp. – December 16, 2021) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or “the Company”), a leading global psychedelics company, today unveiled a new series of psilocybin-assisted wellness retreats for 2022. Set in Jamaica’s idyllic Good Hope Villas, located in Trelawny parish, the new retreats follow the […]

MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation

November 30th, 2021 - Ryan Allway

R&D project on psilocybin’s benefits in treating diseases of the brain   VANCOUVER, BC, Nov. 30, 2021 /PRNewswire/ – MYND Life Sciences Inc. (“MYND” or the “Company“) (CSE: MYND) (OTC: MYNDF) is pleased and extremely grateful to acknowledge the financial contribution from the Government of Canada towards an important component of its research and development into the positive effects of psilocybin […]

Diamond Therapeutics Announces First Patient Dosed in Health Canada Approved Trial Evaluating Low-Dose Psilocybin

November 8th, 2021 - Ryan Allway

World’s first systematic, pharmacokinetic/pharmacodynamic study of non-psychedelic doses of psilocybin   TORONTO, Nov. 8, 2021 /CNW/ – Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on non-hallucinogenic, psychedelic-based therapies for use in the treatment of mental health, today announced the dosing of the first cohort of its Phase 1 clinical trial. This is the […]

MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical Trial

October 13th, 2021 - Ryan Allway

Evaluating the efficacy of psilocybin-assisted psychotherapy in treatment resistant depression   VANCOUVER, BC, Oct. 13, 2021 /CNW/ – MYND Diagnostics Inc., a wholly-owned subsidiary of MYND Life Sciences (CSE: MYND) (OTC: MYNDF) is pleased to announce that the Company’s proprietary biomarker test technology will be a pivotal component of a proposed clinical trial seeking partial funds from a $15 million fund […]

Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application

October 5th, 2021 - Ryan Allway

—Company utilizes green chemistry to stabilize natural product with higher yields   VANCOUVER, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to advise of a recent patent […]

Lobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than Monotherapy in mTBI and PTSD

September 28th, 2021 - Ryan Allway

Combination Therapy with Psilocybin plus NAC (N-Acetylcysteine) Is Statistically Significantly Better Than Either Agent Alone or Placebo in a Rodent Model of mTBI and PTSD   VANCOUVER, BC, Sept. 28, 2021 /PRNewswire/ – Lobe Sciences Ltd. (“Lobe” or the “Company“) (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce interim data from its preclinical research studies, in […]

NeonMind Announces DTC Eligibility

August 25th, 2021 - Ryan Allway

VANCOUVER, BC / ACCESSWIRE / August 25, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FFE:6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today that its common shares listed on the OTCQB under the symbol “NMDBF” are now eligible for […]

Ketamine One to Provide Scent-Enabled Virtual Reality Via Exclusive Agreement For Psychedelic Molecules with OVR Technology

August 4th, 2021 - Ryan Allway

Agreement Provides Ketamine One With First-of-its-Kind VR Scent Capabilities to Generate More Realistic Immersive Experiences and Help Improve Patient Treatment Outcomes   Vancouver, British Columbia, August 4, 2021 / Globe Newswire / – KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and […]

Mindset Files International Patent Application for its Novel Psilocybin Synthesis Method

July 27th, 2021 - Ryan Allway

‍Toronto, Ontario, July 27, 2021 – Mindset Pharma Inc. (CSE:MSET) (FSE:9DF) (OTCQB:MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized next-generation psychedelic medicines to treat neurological and neuropsychiatric disorders with unmet medical needs, today announced that it has filed an international patent application for its novel psilocybin synthesis method. The application claims […]

Tryp Therapeutics Announces Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

July 21st, 2021 - Ryan Allway

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia   San Diego, California–(Newsfile Corp. – July 21, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory […]

Wake Network, Inc. and the Lieber Institute for Brain Development Announce Research Collaboration

July 21st, 2021 - Ryan Allway

July 21, 2021 – Wake Network, Inc., a global leader in psilocybin mushroom research, production and the developer of genomics-based integration therapies, is pleased to announce a collaboration with the Lieber Institute for Brain Development (the ” Lieber Institute “), a non-profit research Institution and an international leader in translating genetics into brain function, to develop […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading